Non-alcoholic fatty liver disease (NAFLD) includes a range of liver conditions unrelated to alcohol consumption that results in inflammation and fibrosis. NAFLD may progress to non-alcoholic steatohepatitis (NASH), cirrhosis, or liver failure; and is closely linked to metabolic syndromes through activation of glucose and lipogenesis-regulating transcription factors, such as FOXO1.
Download this complimentary application note to explore the use of an HTRF assay for the evaluation of FOXO1 in a fatty liver disease model and evaluate:
We are committed to your privacy. Revvity needs the contact information you provide us to keep you aware about relevant content, products, and services. You may unsubscribe from these communications at any time. For more information check out our Privacy Policy.